Impact of Bifidobacterium animalis subsp. lactis HN019 probiotic in the prevention of periodontitis associated with immunosuppression.
antineoplastic agents
bifidobacterium animalis
periodontitis
probiotics
Journal
Journal of periodontology
ISSN: 1943-3670
Titre abrégé: J Periodontol
Pays: United States
ID NLM: 8000345
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
15
08
2022
received:
21
03
2022
accepted:
20
09
2022
medline:
29
3
2023
pubmed:
18
10
2022
entrez:
17
10
2022
Statut:
ppublish
Résumé
This study evaluated the effects of the probiotic Bifidobacterium animalis subsp. lactis HN019 (HN019) in the development of experimental periodontitis (EP) in rats submitted to chemotherapy (5-fluorouracil [5FU]). Eighty male rats were divided into the following groups: control (C); treated with 5FU (60 mg/kg at day 30 and 40 mg/kg at day 32); treated with probiotic (HN019) (daily, for 44 days, starting at day 0); treatment with 5FU and probiotic (5FU-HN019); only EP (EP) (ligature placed on lower first molars at day 30, maintained for 14 days); EP and treatment with 5FU (EP-5FU); EP and treatment with probiotic (EP-HN019); and EP and treatment with 5FU and probiotic (EP-5FU-HN019). Euthanasia occurred at day 44. Morphometric, histomorphometric, microtomographic, immunohistochemical, immunoenzymatic, and gene expressions analyses were performed. The data obtained were statistically analyzed (p < 0.05). The EP-5FU-HN019 group showed less bone and connective tissue loss when compared with EP-5FU group, while EP-HN019 and EP-5FU-HN019 groups had greater bone volume than EP and EP-5FU groups, respectively (p < 0.05). A decrease in immunostaining for tartrate-resistant acid phosphatase and RANKL, an increase for osteoprotegerin and lower interleukin-1β levels were observed in EP-5FU-HN019 group, when compared with EP-5FU group (p < 0.0001). Probiotic therapy led to an increase in the proportions of B. lactis in the feces (p = 0.0018), but not in the biofilm, and reduced the expression of Fusobacterium nucleatum and Prevotella intermedia in the biofilm (p < 0.0001). B. lactis HN019 reduced the severity of EP in rats submitted to chemotherapy, modulating immunoinflammatory parameters in periodontal tissues and reducing periodontopathogens expression on biofilm in rats submitted to chemotherapy.
Sections du résumé
BACKGROUND
This study evaluated the effects of the probiotic Bifidobacterium animalis subsp. lactis HN019 (HN019) in the development of experimental periodontitis (EP) in rats submitted to chemotherapy (5-fluorouracil [5FU]).
METHODS
Eighty male rats were divided into the following groups: control (C); treated with 5FU (60 mg/kg at day 30 and 40 mg/kg at day 32); treated with probiotic (HN019) (daily, for 44 days, starting at day 0); treatment with 5FU and probiotic (5FU-HN019); only EP (EP) (ligature placed on lower first molars at day 30, maintained for 14 days); EP and treatment with 5FU (EP-5FU); EP and treatment with probiotic (EP-HN019); and EP and treatment with 5FU and probiotic (EP-5FU-HN019). Euthanasia occurred at day 44. Morphometric, histomorphometric, microtomographic, immunohistochemical, immunoenzymatic, and gene expressions analyses were performed. The data obtained were statistically analyzed (p < 0.05).
RESULTS
The EP-5FU-HN019 group showed less bone and connective tissue loss when compared with EP-5FU group, while EP-HN019 and EP-5FU-HN019 groups had greater bone volume than EP and EP-5FU groups, respectively (p < 0.05). A decrease in immunostaining for tartrate-resistant acid phosphatase and RANKL, an increase for osteoprotegerin and lower interleukin-1β levels were observed in EP-5FU-HN019 group, when compared with EP-5FU group (p < 0.0001). Probiotic therapy led to an increase in the proportions of B. lactis in the feces (p = 0.0018), but not in the biofilm, and reduced the expression of Fusobacterium nucleatum and Prevotella intermedia in the biofilm (p < 0.0001).
CONCLUSION
B. lactis HN019 reduced the severity of EP in rats submitted to chemotherapy, modulating immunoinflammatory parameters in periodontal tissues and reducing periodontopathogens expression on biofilm in rats submitted to chemotherapy.
Identifiants
pubmed: 36245273
doi: 10.1002/JPER.22-0146
doi:
Substances chimiques
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
389-404Informations de copyright
© 2022 American Academy of Periodontology.
Références
Bartold PM, Van Dyke TE. Host modulation: controlling the inflammation to control the infection. Periodontol 2000. 2017;75(1):317-329. doi:10.1111/prd.12169
Socransky SS, Haffajee AD, Cugini MA, Smith C. Microbial complexes in subgingival plaque. J Clin Periodontol. 1998;25(2):134-144. doi:10.1111/j.1600-051X.1998.tb02419.x
Teles FRF, Teles RP, Uzel NG, et al. Early microbial succession in redeveloping dental biofilms in periodontal health and disease. J Periodontal Res. 2012;47(1):95-104. doi:10.1111/j.1600-0765.2011.01409.x
Prucsi Z, Ptonczynska A, Potempa J, Sochalska M. Uncovering the oral dysbiotic microbiota as masters of neutrophil responses in the pathobiology of periodontitis. Front Microbiol. 2021;12:729717. doi:10.3389/fmicb.2021.729717
Krugan S, Kansal S, Nguyen D, et al. Strain-specific impact of fusobacterium nucleatum on neutrophil function. J Periodontol. 2017;88(4):380-389. Epub 2016 Oct 20. doi:10.1902/jop.2016.160212
Curtis MA, Diaz PI, Van Dyke TEV. The role of the microbiota in periodontal disease. Periodontol 2000. 2020;83(1):14-25. doi:10.1111/prd.12296
Gheisary Z, Mahmood R, Shivanantham AH, et al. The clinical, microbiological, and immunological effects of probiotic supplementation on prevention and treatment of periodontal diseases: a systematic review and meta-analysis. Nutrients. 2022;14(5):1036. doi:10.3390/nu14051036
Hajishengallis G, Kajikawa T, Hajishengallis E, et al. Complement-dependent mechanisms and interventions in periodontal disease. Front Immunol. 2019;10:406. doi:10.3389/fimmu.2019.00406
Sima C, Viniegra A, Glougauer M. Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis. J L Leukoc Biol. 2019;105(3):473-487. doi:10.1002/JLB.1RU0818-310R
Haytac MC, Kunin AA, Belenova IA. Probiotics and oral-periodontal health. EPMA J. 2014;5(Suppl 1):A125. Available from: http://epmajournal.biomedcentral.com/articles/10.1186/1878-5085-5-S1-A125
Hallström H, Lindgren S, Widén C, Renvert S, Twetman S. Probiotic supplements and debridement of peri-implant mucositis: a randomized controlled trial. Acta Odontol Scand Early Online. 2016;74(1):60-66. https://www.tandfonline.com/doi/abs/10.3109/00016357.2015.1040065?journalCode=iode20
Messora MR, Pereira LJ, Foureaux R, et al. Favourable effects of Bacillus subtilis and Bacillus licheniformis on experimental periodontitis in rats. Arch Oral Biol. 2016;66:108-119.
Aljewicz M, Cichosz G. The effect of probiotic Lactobacillus rhamnosus HN001 on the invitro availability of minerals from cheeses and cheese-like products. LWT - Food Sci Technol. 2015;60(2):841-847. doi:10.1016/j.lwt.2014.09.052
Ranadheera R, Baines SK, Adams MC. Importance of food in probiotic efficacy. Food Res Int. 2010;43(1):1-7. doi:10.1016/j.foodres.2009.09.009
Whitford EJ, Cummins AG, Butler RN, et al. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU). Cancer Biol Ther. 2009;8(6):505-511.
Wibowo N, Bardosono S, Irwinda R. Effects of Bifidobacterium animalis lactis HN019 (DR10TM), inulin, and micronutrient fortified milk on faecal DR10TM, immune markers, and maternal micronutrients among Indonesian pregnant women. Asia Pac J Clin Nutr. 2016;25(Suppl 1):S102-S110. http://www.ncbi.nlm.nih.gov/pubmed/28027638
Jäsberg H, Söderling E, Endo A, Beighton D, Haukioja A. Bifidobacteria inhibit the growth of Porphyromonas gingivalis but not of Streptococcus mutans in an in vitro biofilm model. Eur J Oral Sci. 2016;124(3):251-258.
Toiviainen A, Jalasvuori H, Lahti E, et al. Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults. Clin Oral Investig. 2015;19(1):77-83.
Oliveira LFF, Salvador SL, Silva PHF, et al. Benefits of bifidobacterium animalis subsp lactis probiotic in experimental periodontitis. J Periodontol. 2017;88(2):197-208. http://www.ncbi.nlm.nih.gov/pubmed/27660886
Ricoldi MST, Furlaneto FAC, Oliveira LFF, et al. Effects of the probiotic Bifidobacterium animalis subsp. lactis on the non-surgical treatment of periodontitis. A histomorphometric, microtomographic and immunohistochemical study in rats. PLoS One. 2017;12(6):1-15.
Invernici MM, Salvador SL, Silva PHF, et al. Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: a randomized clinical trial. J Clin Periodontol. 2018:0-2.
Invernici MM, Furlaneto FAC, Salvador SL, et al. Bifidobacterium animalis subsp lactis HN019 presents antimicrobial potential against periodontopathogens and modulates the immunological response of oral mucosa in periodontitis patients. Ojcius DM, ed. PLoS One. 2020;15(9):e0238425. https://dx.plos.org/10.1371/journal.pone.0238425
Gerhard D, Sousa F, Andraus RAC, et al. Probiotic therapy reduces inflammation and improves intestinal morphology in rats with induced oral mucositis. Braz Oral Res. 2017;31:e71.
Danos O, Davies K, Lehn P, Mulligan R. The ARRIVE guide-lines, a welcome improvement to standards for reporting anima lresearch. J Gene Med. 2010;12:559-560.
Messora MR, Oliveira LFF, Foureaux RC, et al. Probiotic therapy reduces periodontal tissue destruction and improves the intestinal morphology in rats with ligature-induced periodontitis. J Periodontol. 2013;84(12):1818-1826. http://www.ncbi.nlm.nih.gov/pubmed/23327675
Levi Y, Novais GS, Dias RB, et al. Effects of the prebiotic mannan oligosaccharide on the experimental periodontitis in rats. J Clin Periodontol. 2018;45(9):1078-1089.
Theodoro LH, Longo M, Ervolino E, et al. Effect of low-level laser therapy as an adjuvant in the treatment of periodontitis induced in rats subjected to 5-fluorouracil chemotherapy. J Periodontal Res. 2016;51(5):669-680.
Foureaux RDC, Messora MR, de Oliveira LF, et al. Effects of probiotic therapy on metabolic and inflammatory parameters of rats with ligature-induced periodontitis associated with restraint stress. J Periodontol. 2014;85(7):975-983. doi:10.1902/jop.2013.130356
Furlaneto FAC, Nunes NLT, Oliveira Filho IL, et al. Effects of locally administered tiludronic acid on experimental periodontitis in rats. J Periodontol. 2014;85(9):1291-1301. http://doi.wiley.com/10.1902/jop.2014.130581
Cardoso RS, Messora MR, Silva PHF, et al. Effects of Bifidobac-terium animalis subsp. lactisHN019 on ligature-induced periodontitis in rats with experimental rheumatoid arthritis. Benef Microbes. 2020;11:33-46.
Junick J, Blaut M. Quantification of human fecal Bifidobacterium species by use of quantitative real-time PCR analysis targeting the groEL gene. Appl Environ Microbiol. 2012;78(8):2613-2622.
Parvaneh K, Ebrahimi M, Sabran MR, et al. Probiotics (Bifidobacterium longum) increase bone mass density and upregulate Sparc and Bmp-2 genes in rats with bone loss resulting from ovariectomy. Biomed Res Int. 2015;2015:897639.https://www.hindawi.com/journals/bmri/2015/897639/
Pompe E, Bartstra J, Verhaar HJ, et al. Bone density loss on computed tomography at 3-year follow-up in current compared to former male smokers. Eur J Radiol. 2017;89:177-181. doi:10.1016/j.ejrad.2017.02.011
Collins FL, Rios-arce ND, Schepper JD, Parameswaran N, Mccabe LR. The potential of probiotics as a therapy for osteoporosis. Bugs Drugs. 2017:213-233. http://www.asmscience.org/content/book/10.1128/9781555819705.chap9
Bickel M, Axtelius B, Solioz C, Attström R. Cytokine gene expression in chronic periodontitis. J Clin Periodontol. 2001;28(9):840-847. http://doi.wiley.com/10.1034/j.1600-051x.2001.028009840.x
Mege J-L, Meghari S, Honstettre A, Capo C, Raoult D. The two faces of interleukin 10 in human infectious diseases. Lancet Infect Dis. 2006;6(9):557-569. https://linkinghub.elsevier.com/retrieve/pii/S1473309906705771
Dai J, Bi L, Lin J, Qi F. Evaluation of interleukin-10 producing CD19 + B cells in human gingival tissue. Arch Oral Biol. 2017;84:112-117. https://linkinghub.elsevier.com/retrieve/pii/S0003996917302807
Lim JH, Um HJ, Park JW, Lee IK, Know TK. Interleukin-1beta promotes the expression of monocyte chemoattractant protein-1 in human aorta smooth muscle cells via multiple signaling pathways. Exp Mol Med. 2009;41(10):757-764. doi:10.3858/emm.2009.41.10.082
Zhang JM, An J. Cytokines, inflammation and pain. Int Anesthesiol Clin Spring. 2007;45(2):27-37. doi:10.1097/AIA.0b013e318034194e
Longo M, Garcia VG, Ervolino E, et al. Multiple aPDT sessions on periodontitis in rats treated with chemotherapy: histomorphometrical, immunohistochemical, immunological and microbiological analyses. Photodiagnosis Photodyn Ther. 2019;25:92-102. Epub 2018 Nov 20. doi:10.1016/j.pdpdt.2018.11.014
VanderVeen BN, Sougiannis AT, Velzquez KT, Carson J, Fan D, Murphy EA. The acute effects of 5 fluorouracil on skeletal muscle resident and infiltrating immune cells in mice. Front Physiol. 2020;11:593468. eCollection 2020. doi:10.3389/fphys.2020.593468
Miranda TS, Figueiredo NF, Figueiredo LC, Silva H, Rocha F, Duarte PM. Cytokine profiles of healthy and diseased sites in individuals with periodontitis. Arch Oral Biol. 2020;120:104957. doi:10.1016/j.archoralbio.2020.104957
Garlet GP. Destructive and protective roles of cytokines in periodontitis: a re-appraisal from host defense and tissue destruction viewpoints. J Dent Res. 2010;89(12):1349-1363. doi:10.1177/0022034510376402
Monastero RN, Pentyala S. Cytokines as biomarkers and their respective clinical cutoff levels. Int J Inflam. 2017;2017:4309485. doi:10.1155/2017/4309485
Morikawa M, Derunck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):a021873. doi:10.1101/cshperspect.a021873
Matarese G, Isola G, Anastasi GP, et al. Immunohistochemical analysis of TGF-β1 and VEGF in gingival and periodontal tissues: a role of these biomarkers in the pathogenesis of scleroderma and periodontal disease. Int J Mol Med. 2012;30(3):502-508. Epub 2012 Jun 11. doi:10.3892/ijmm.2012.1024
Gurkan A, Emingil G, Cinarcik S, Berdeli A. Gingival crevicular fluid transforming growth factor-beta1 in several forms of periodontal disease. Arch Oral Biol. 2006;51(10):906-912. Epub 2006 Jun 19. doi:10.1016/j.archoralbio.2006.04.008
Haque S, Morris JC. Transforming growth factor-β: a therapeutic target for câncer. Hum Vaccin Immunother. 2017;13(8):1741-1750. Epub 2017 Jun 2. doi:10.1080/21645515.2017.1327107
Zhang M, Zhang YY, Chen Y, Wang J, Wang Q, Lu H. TGF-β signaling and resistance to cancer therapy. Front Cell Dev Biol. 2021;9:786728. eCollection 2021. doi:10.3389/fcell.2021.786728
Zhao P, Ma YG, Zhao Y, et al. MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer. Cancer Chemother Pharmacol. 2019;84(2):427-439. Epub 2019 May 13. doi:10.1007/s00280-019-03866-7
Zhang B, Zhang B, Chen X, et al. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br J Cancer. 2014;110(4):946-957. Epub 2014 Jan 2. doi:10.1038/bjc.2013.789
Liu C, Zhang ZY, Dong K, Guo XK. Adhesion and immunomodulatory effects of bifidobacterium lactis HN019 on intestinal epithelial cells INT-407. World J Gastroenterol. 2010;16(18):2283-2290.
Gillor O, Etzion A, Riley MA. The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol. 2008;81(4):591-606. http://link.springer.com/10.1007/s00253-008-1726-5
Gordon DM. The potential of bacteriocin-producing probiotics and associated caveats. Future Microbiol. 2009;4(8):941-943. https://www.futuremedicine.com/doi/10.2217/fmb.09.78
Haukioja A, Yli-Knuuttila H, Loimaranta V, et al. Oral adhesion and survival of probiotic and other lactobacilli and bifidobacteria in vitro. Oral Microbiol Immunol. 2006;21(5):326-332. https://onlinelibrary.wiley.com/doi/10.1111/j.1399-302X.2006.00299.x
Neves BG, Stipp RN, Bezerra D, et al. Quantitative analysis of biofilm bacteria according to different stages of early childhood caries. Arch Oral Biol. 2018;96:155-161. https://linkinghub.elsevier.com/retrieve/pii/S0003996918305910
Booijink CC, Zoetendal EG, Kleerebezem M, de Vos WM. Microbial communities in the human small intestine: coupling diversity to metagenomics. Future Microbiol. 2007;2(3):285-295. https://www.futuremedicine.com/doi/10.2217/17460913.2.3.285
Booijink C, El-Aidy S, Rajilić-Stojanović M, et al. High temporal and inter-individual variation detected in the human ileal microbiota. Environ Microbiol. 2010;12(12):3213-3227. https://onlinelibrary.wiley.com/doi/10.1111/j.1462-2920.2010.02294.x
Whitmore SE, Lamont RJ. Oral bacteria and cancer. PLoS Pathog. 2014;10(3):e1003933. eCollection 2014 Mar. doi:10.1371/journal.ppat.1003933
Chung PC, Chan TC. Association between periodontitis and all-cause and cancer mortality: retrospective elderly community cohort study. BMC Oral Health. 2020;20(1):168. doi:10.1186/s12903-020-01156-w
Jia M, Wu Z, Vogtmann E, et al. The association between periodontal disease and breast cancer in a prospective cohort study. Cancer Prev Res (Phila). 2020;13(12):1007-1016. Epub 2020 Jul 29. doi:10.1158/1940-6207.CAPR-20-0018
Teughels W, Loozen G, Quirynen M. Do probiotics offer opportunities to manipulate the periodontal oral microbiota? J Clin Periodontol. 2011;1:159-177.